Breast Cancer, Version 3.2024

被引：156

作者：

Gradishar, William J. ^{[1
]}

Moran, Meena S. ^{[2
]}

Abraham, Jame ^{[3
,4
]}

Abramson, Vandana ^{[5
]}

Aft, Rebecca ^{[6
,7
]}

Agnese, Doreen ^{[8
,9
]}

Allison, Kimberly H. ^{[10
]}

Anderson, Bethany ^{[11
]}

Bailey, Janet ^{[12
]}

Burstein, Harold J. ^{[13
]}

Chen, Nan ^{[14
]}

Chew, Helen ^{[15
]}

Dang, Chau ^{[16
]}

Elias, Anthony D. ^{[17
]}

Giordano, Sharon H. ^{[18
]}

Goetz, Matthew P. ^{[19
]}

Jankowitz, Rachel C. ^{[20
]}

Javid, Sara H. ^{[21
]}

Krishnamurthy, Jairam ^{[22
]}

Leitch, A. Marilyn ^{[23
]}

Lyons, Janice ^{[3
,4
]}

McCloskey, Susie ^{[24
]}

Mcshane, Melissa ^{[25
]}

Mortimer, Joanne ^{[26
]}

Patel, Sameer A. ^{[25
]}

Rosenberger, Laura H. ^{[27
]}

Rugo, Hope S. ^{[28
]}

Santa-Maria, Cesar ^{[29
]}

Schneider, Bryan P. ^{[30
]}

Smith, Mary Lou ^{[31
]}

Soliman, Hatem ^{[32
]}

Stringer-Reasor, Erica M. ^{[33
]}

Telli, Melinda L. ^{[10
]}

Wei, Mei ^{[34
]}

Wisinski, Kari B. ^{[11
]}

Yeung, Kay T. ^{[35
]}

Young, Jessica S. ^{[36
]}

Schonfeld, Ryan ^{[37
]}

Kumar, Rashmi ^{[37
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[2] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[3] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[9] Solove Res Inst, Columbus, OH USA

[10] Stanford Canc Inst, Stanford, CA USA

[11] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[12] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[13] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[14] UChicago, Med Comprehens Canc Ctr, Chicago, IL USA

[15] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA USA

[16] Mem Sloan Kettering Canc Ctr, New York, NY USA

[17] Univ Colorado, Canc Ctr, Boulder, CO USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[19] Mayo Clin, Comprehens Canc Ctr, Rochester, MN USA

[20] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[21] Fred Hutchinson Canc Ctr, Seattle, WA USA

[22] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[23] UT Southwestern, Simmons Comprehens Canc Ctr, Dallas, TX USA

[24] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[25] Fox Chase Canc Ctr, Philadelphia, PA USA

[26] City Hope Natl Med Ctr, Duarte, CA USA

[27] Duke Canc Inst, Durham, NC USA

[28] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[29] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MA USA

[30] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[31] Res Advocacy Network, Plano, TX USA

[32] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[33] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[34] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[35] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[36] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[37] Natl Comprehens Canc Network, Cleveland, OH USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 05期

关键词：

GROWTH-FACTOR RECEPTOR; ADJUVANT ENDOCRINE THERAPY; 21-GENE RECURRENCE SCORE; TRIAL COMPARING DOXORUBICIN; PATIENT-LEVEL METAANALYSIS; EPIRUBICIN PLUS DOCETAXEL; PLACEBO-CONTROLLED TRIAL; BONE-MINERAL DENSITY; 7-YEAR FOLLOW-UP; QUALITY-OF-LIFE;

D O I：

10.6004/jnccn.2024.0035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

引用

页码：331 / 357

页数：27

共 180 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

Abe O, 1998, LANCET, V352, P930

[3] No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications [J].

Ahern, Thomas P. ;

Pedersen, Lars ;

Cronin-Fenton, Deirdre P. ;

Sorensen, Henrik Toft ;

Lash, Timothy L. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (09) :2562-2564

[4] Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Ravdin, Peter M. ;

Farrar, William B. ;

Burton, Gary V. ;

Ketchel, Steven J. ;

Cobau, Charles D. ;

Levine, Ellis G. ;

Ingle, James N. ;

Pritchard, Kathleen I. ;

Lichter, Allen S. ;

Schneider, Daniel J. ;

Abeloff, Martin D. ;

Henderson, I. Craig ;

Muss, Hyman B. ;

Green, Stephanie J. ;

Lew, Danika ;

Livingston, Robert B. ;

Martino, Silvana ;

Osborne, C. Kent .

LANCET, 2009, 374 (9707) :2055-2063

[5] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[6]

Allred C, 2009, J NATL COMPR CANC NE, V7, pS1

[7] HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study [J].

Arpino, G ;

Green, SJ ;

Allred, DC ;

Lew, D ;

Martino, S ;

Osborne, CK ;

Elledge, RM .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5670-5676

[8] Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial [J].

Baek, Soo Yeon ;

Noh, Woo Chul ;

Ahn, Sei-Hyun ;

Kim, Hyun-Ah ;

Ryu, Jai Min ;

Kim, Seung Il ;

Lee, Eun-Gyeong ;

Im, Seock-Ah ;

Jung, Yongsik ;

Park, Min Ho ;

Park, Kyong Hwa ;

Kang, Su Hwan ;

Jeong, Joon ;

Park, Eunhwa ;

Kim, Sung Yong ;

Lee, Min Hyuk ;

Kim, Lee Su ;

Lim, Woosung ;

Kim, Seonok ;

Kim, Hee Jeong .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (31) :4864-+

[9]

Bang SM, 2000, CANCER, V89, P2521, DOI 10.1002/1097-0142(20001215)89:12<2521::AID-CNCR2>3.0.CO

[10]

2-F

← 1 2 3 4 5 6 7 8 9 10 →